RhumbLine Advisers
CO

RhumbLine Advisers’s Global Cord Blood Corporation CO Stock Holding History

RhumbLine Advisers’s Portfolio CO Stock Details CO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$12.7K Hold
13,362
– – ﹤0.01% 3869
2026
Q1 		$14K Hold
13,362
– – ﹤0.01% 3764
2025
Q4 		$12.7K Hold
13,362
– – ﹤0.01% 3823
2025
Q3 		$13.5K Sell
13,362
-11,455
-46% -$11.6K ﹤0.01% 3825
2025
Q2 		$37.2K Hold
24,817
– – ﹤0.01% 3717
2025
Q1 		$22.3K Sell
24,817
-19,940
-45% -$17.9K ﹤0.01% 3722
2024
Q4 		$67.1K Hold
44,757
– – ﹤0.01% 3588
2024
Q3 		$78.3K Hold
44,757
– – ﹤0.01% 3582
2024
Q2 		$51.5K Sell
44,757
-7,937
-15% -$9.13K ﹤0.01% 3672
2024
Q1 		$71.1K Hold
52,694
– – ﹤0.01% 3541
2023
Q4 		$64.3K Buy
52,694
+7,937
+18% +$9.68K ﹤0.01% 3570
2023
Q3 		$55.5K Hold
44,757
– – ﹤0.01% 3621
2023
Q2 		$47K Buy
+44,757
New +$47K ﹤0.01% 3685

Other funds holding CO

LC
Luminist Capital Grand Rapids, Michigan $89M AUM 17.66% 1-Year Est. Return

RhumbLine Advisers's CO Position: Q2 2026 in Review

RhumbLine Advisers held its Global Cord Blood Corporation (CO) position steady in Q2 2026 at 13,362 shares worth $12.7K. The position accounts for ﹤0.01% of the portfolio, ranked #3869.

RhumbLine Advisers first reported a position in CO in Q2 2023 and has held it in 13 quarters since. The position peaked at $78.3K in Q3 2024. 2 funds tracked by Wall St. Rank hold CO as of Q2 2026.

  • RhumbLine Advisers held 13,362 shares of Global Cord Blood Corporation worth $12.7K as of Q2 2026.
  • RhumbLine Advisers left its Global Cord Blood Corporation share count unchanged in Q2 2026.
  • Global Cord Blood Corporation made up ﹤0.01% of RhumbLine Advisers's portfolio in Q2 2026, its #3869 holding.
  • RhumbLine Advisers first reported a position in Global Cord Blood Corporation in Q2 2023 and has held it in 13 quarters since.
  • RhumbLine Advisers's Global Cord Blood Corporation position peaked at $78.3K in Q3 2024.
  • 2 funds tracked by Wall St. Rank held Global Cord Blood Corporation as of Q2 2026.

Based on RhumbLine Advisers's 13F filing for Q2 2026, filed 12 Aug 2026.